GlassScriptPhysician profile
Mary Jane Woods
NPI 1558807511
$3,597.08
in general payments reported to CMS, 2019-2025
19 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.63 · 2023: $38.07 · 2024: $3,131 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Travel and Lodging: $1,316 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.99 |
| Travel and Lodging | $1,316.37 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,281.46 | 2024-2025 | Barostim Neo System |
| Abbott Laboratories | $487.61 | 2024-2025 | Cardiomems |
| Kestra Medical Technology Services, INC. | $295.35 | 2024-2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $235.74 | 2024-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $221.06 | 2024 | Wainua, Brilinta, Farxiga |
| Merck Sharp & Dohme LLC | $205.18 | 2024-2025 | Verquvo, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $199.08 | 2024 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $193.90 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $93.52 | 2024-2025 | |
| United Therapeutics Corporation | $65.96 | 2024 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $65.14 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.24 | 2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $49.00 | 2024 | |
| Novo Nordisk INC | $45.16 | 2024 | Rybelsus, Ozempic |
| Pfizer INC. | $27.97 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.35 | 2024 | Amvuttra |
| Daiichi Sankyo INC. | $18.51 | 2024 | Injectafer |
| Boston Scientific Corporation | $14.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Jane Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.